Document is current
Any future updates will be listed below
-
Authors
Noble, Joyce Carol https://orcid.org/0000-0002-4450-429X
Lentini, Antonio https://orcid.org/0000-0003-1239-5495
Hagemann-Jensen, Michael https://orcid.org/0000-0002-6423-8216
Sandberg, Rickard https://orcid.org/0000-0001-6473-1740
Reinius, Björn https://orcid.org/0000-0002-7021-5248
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2022-01620)
Svenska Sällskapet för Medicinsk Forskning (CG-22-0260-H-02)
Knut och Alice Wallenbergs Stiftelse (2021.0142, 2022.0146)
- License Information
-
More Information
Article History
Received: 28 March 2024
Accepted: 19 September 2024
First Online: 27 September 2024
Competing interests
: J.C.N., A.L., and B.R. have filed patent applications on synthetic RNase inhibitors in scRNAseq and other applications and are co-founders of SEQURNA AB, making available the thermostable RNase inhibitor mix herein described as a quality-controlled kit. The composition of the inhibitor mix is undisclosed. J.C.N., A.L., M.H.J., R.S., and B.R. are shareholders of SEQURNA AB.
